Literature DB >> 10952625

Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Y Dong1, X Zhao, B N Kreiswirth, K Drlica.   

Abstract

The mutant prevention concentration (MPC) of a C-8-methoxy fluoroquinolone exhibited a narrow distribution for 14 genetically diverse clinical isolates of Mycobacterium tuberculosis, indicating that results from single-isolate studies are likely to be representative. When one isolate was challenged with a variety of antituberculosis agents, C-8-methoxy fluoroquinolones were exceptional in having MPCs below the maximum concentration attained in serum by use of commonly recommended doses.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10952625      PMCID： PMC90115          DOI： 10.1128/AAC.44.9.2581-2584.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus.

Authors:  Y Dong; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations.

Authors:  J Zhou; Y Dong; X Zhao; S Lee; A Amin; S Ramaswamy; J Domagala; J M Musser; K Drlica
Journal:  J Infect Dis       Date:  2000-07-24       Impact factor: 5.226

3.  Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology.

Authors:  P J Bifani; B Mathema; Z Liu; S L Moghazeh; B Shopsin; B Tempalski; J Driscol; R Frothingham; J M Musser; P Alcabes; B N Kreiswirth
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

4.  Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.

Authors:  J T Sullivan; M Woodruff; J Lettieri; V Agarwal; G J Krol; P T Leese; S Watson; A H Heller
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.

Authors:  G Acocella; A Nonis; G Perna; E Patane; G Gialdroni-Grassi; C Grassi
Journal:  Am Rev Respir Dis       Date:  1988-10

6.  Pharmacokinetics of cycloserine and terizidone. A comparative study.

Authors:  L Zítková; J Tousek
Journal:  Chemotherapy       Date:  1974       Impact factor: 2.544

7.  Absorption, excretion and metabolism of capreomycin in normal and diseased states.

Authors:  H R Black; R S Griffith; A M Peabody
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

8.  Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration study.

Authors:  G Acocella; R Conti; M Luisetti; E Pozzi; C Grassi
Journal:  Am Rev Respir Dis       Date:  1985-09

Review 9.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

10.  Comparative pharmacokinetics of BB-K8 and kanamycin in dogs and humans.

Authors:  B E Cabana; J G Taggart
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191
View more
  37 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 3.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

4.  Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Elia Gómez G de la Pedrosa; Rafael Cantón; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.

Authors:  Xinying Li; Noriel Mariano; James J Rahal; Carl M Urban; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; George N Konstantinides; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.

Authors:  Aude Ferran; Véronique Dupouy; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

8.  Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model.

Authors:  Aude A Ferran; Anne-Sylvie Kesteman; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2009-06-01       Impact factor: 5.191

9.  Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.

Authors:  Heather J Smith; Michael Walters; Tamiko Hisanaga; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 10.  Drug interactions and the evolution of antibiotic resistance.

Authors:  Pamela J Yeh; Matthew J Hegreness; Aviva Presser Aiden; Roy Kishony
Journal:  Nat Rev Microbiol       Date:  2009-06       Impact factor: 60.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.